ACE/ACE2 axis in cardiovascular disease and COVID-19: Molecular insights and therapeutic perspectives
Journal of Cardiovascular and Thoracic Research · 30.03.2026 · 18 (1) · 15-25
DOI: 10.34172/jcvtr.026.33335 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular and Thoracic Research, online erschienen am 30.03.2026. Verfasst von Sony Peter und 10 weiteren Autor:innen. Beteiligte Einrichtung: Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India. Die Arbeit nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The renin-angiotensin system (RAS) plays a central role in regulating blood pressure and cardiovascular health. Angiotensin-converting enzyme (ACE) facilitates the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that contributes to hypertension and heart failure. Conversely, ACE2 converts angiotensin II into angiotensin-(1-7), a vasodilator with protective cardiovascular effects. An imbalance between ACE and ACE2 activities has been increasingly associated with the progression of cardiovascular diseases and complications related to COVID-19. This review analyzed 100 relevant studies published up to May 2024, identified through a comprehensive literature search on PubMed and Scopus. The findings highlighted that dysregulation of the ACE/ACE2 axis exacerbates cardiovascular dysfunction. The interaction of SARS-CoV-2 with ACE2 reduces its protective function, intensifying inflammatory responses and leading to complications such as lung injury and heart failure. Additionally, genetic polymorphisms in ACE and ACE2 influence individual susceptibility and severity of COVID-19. Promising therapeutic strategies, including ACE2-based peptides and angiotensin II receptor modulators, are under investigation but require further clinical validation. Targeting the ACE/ACE2 axis could provide effective treatment options for cardiovascular disease and COVID-19-related complications, warranting further in-depth research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
- Department of Biochemistry, Meenakshi Ammal Dental College & Hospital, Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
- Meenakshi Ammal Dental College & Hospital, Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
- Department of Biochemistry, ACS Medical College & Hospital, Chennai, Tamil Nadu, India.
- Centre for Advanced Genetic Studies, Thiruvananthapuram, Kerala, India.
ORCID-Profile: Sony Peter, Thiruchenduran Mohana, Dinesh Roy Divakaran
Zitieren
APA
Peter, S., Mohana, T., Anandhi, D., Priya, V. S., Sleeba, R. K., Haridas, H. P., Mohanan, M. T., Thoduvayil, S., Mathew, S., Santhamma, D. M., & Divakaran, D. R. (2026). ACE/ACE2 axis in cardiovascular disease and COVID-19: Molecular insights and therapeutic perspectives. Journal of Cardiovascular and Thoracic Research, 18(1), 15-25. https://doi.org/10.34172/jcvtr.026.33335
Vancouver
Peter S, Mohana T, Anandhi D, Priya VS, Sleeba RK, Haridas HP, et al. ACE/ACE2 axis in cardiovascular disease and COVID-19: Molecular insights and therapeutic perspectives. Journal of Cardiovascular and Thoracic Research. 2026;18(1):15-25. doi:10.34172/jcvtr.026.33335
BibTeX
@article{Peter2026,
author = {Peter, Sony and Mohana, Thiruchenduran and Anandhi, Dhanavel and Priya, Vishwanathan Sathya and Sleeba, Romi Keerikkattil and Haridas, Harisree Panikkaveedu and Mohanan, Midhun Thazhissery and Thoduvayil, Swathi and Mathew, Sinha and Santhamma, Dhanya Muraleedharan and Divakaran, Dinesh Roy},
title = {ACE/ACE2 axis in cardiovascular disease and COVID-19: Molecular insights and therapeutic perspectives},
journal = {Journal of Cardiovascular and Thoracic Research},
year = {2026},
volume = {18},
number = {1},
pages = {15--25},
doi = {10.34172/jcvtr.026.33335}
}
EUVIMED